Showing results (1-10 of 181) with videos related to
Sort By:
Pageof 19
Seminars in Radiation Oncology|October 26, 2001
Targeting DNA mismatch repair for radiosensitizationS E Berry, T J KinsellaCancer Research|November 4, 2000
Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanineS E Berry, T W Davis, J E Schupp, et al.Seminars in Oncology|June 1, 1992
Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizersT J KinsellaThe Cancer Journal From Scientific American|July 1, 1996
An approach to the radiosensitization of human tumorsT J KinsellaProgress in Clinical and Biological Research|January 1, 1989
Effects of radiation therapy and chemotherapy on testicular functionT J KinsellaCancer Research|April 23, 1999
The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cellsS E Berry, C Garces, H S Hwang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000
Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study designT J Kinsella, J E Schupp, T W Davis, et al.Cancer|March 1, 1987
Clinical experience with intravenous radiosensitizers in unresectable sarcomasT J Kinsella, E GlatsteinCancer Research|May 30, 1998
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cellsM L Kuo, T J KinsellaSeminars in Oncology|August 1, 1992
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulationC J McGinn, T J KinsellaPageof 19